Clinical Trial Update: Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating fourth-generation safety-engineered CAR T cells for sarcomas, including osteoid sarcoma and Ewing sarcoma, is in progress …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteoid Sarcoma
• Sarcoma

Drugs mentioned

• 4th Generation Safety-engineered CAR T cells (CAR T cells (fourth generation safety-engineered))

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Sarcoma, Osteoid Sarcoma | Phase 1, Phase 2 | Status: UNKNOWN